Navigation Links
Deadly E. Coli Strain Sequenced With Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date
Date:6/15/2011

BRANFORD, Connecticut, June 15, 2011 /PRNewswire/ --


The deadly E. coli O104 strain that has killed dozens and hospitalized thousands across Europe has been sequenced using 454 Life Sciences' benchtop GS Junior sequencing system to generate the "most accurate and detailed genetic analysis to date" of this particularly virulent strain.[1] The sequencing was performed by scientists at the UK's Health Protection Agency and the data has been uploaded onto the National Centre for Biotechnology Information (NCBI) website for use by the scientific community.[2]

The results suggest that the strain has a unique combination of features containing genes from two different types of E. coli as well as its own genes. The sequencing assembly shows that the strain contains two extrachromosomal elements or plasmids which may factor into its pathogenicity. In essence, this strain of E. coli may have 'picked up' some extra genetic material along the way.

"Despite the availability of short read sequencing data from this E. coli outbreak strain for over a week, the short fragmented assembly has offered only limited information on gene order and gene composition," said Chinnappa Kodira, Director of Genomics at 454 Life Sciences. "This long contiguous assembly enables much better characterization of genome structure, horizontal gene transfer and pathogenic islands which are crucial for understanding the emergence of new virulent bacterial strains." The addition of this new long read sequence data from the GS Junior System offers the community the most contiguous sequence to date, and provides a comprehensive assembly on which subsequent genomic analysis can be performed.

The long shotgun reads generated using the 454 Sequencing System allowed the HPA scientists to assemble almost the entire genome into a comprehensive and detailed genomic map of this pathogen within hours. The sequence data will assist in on-going efforts to identify the source of the outbreak, and understand how the strain may have evolved.

"The combination of fast turnaround time and high-quality, long sequencing reads makes the GS Junior an ideal research platform for rapid and comprehensive whole genome analysis in novel pathogen outbreak situations," said Christopher McLeod, President and CEO of 454 Life Sciences. "We are gratified that 454 Life Sciences is helping to improve health care by enabling a quick response to shed some light on potential epidemics."

For more information on 454 Sequencing Systems, visit http://www.454.com

[1]Health Protection Agency press release June 13, 2011: http://www.hpa.org.uk/NewsCentre/NationalPressReleases/2011PressReleases/110613Ecoligenome/

[2]The sequence data can be viewed on the NCBI website http://www.ncbi.nlm.nih.gov/. The GeneBank Project ID is 67929 and the accession number is afpn00000000. The data can also be viewed on the HPA website: http://www.hpa-bioinformatics.org.uk/lgp/genomes.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80'000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: http://www.roche.com.

For life science research only. Not for use in diagnostic procedures.

454, 454 LIFE SCIENCES, 454 SEQUENCING, and GS JUNIOR are trademarks of Roche.

Other brands or product names are trademarks of their respective holders.

For further information please contact: 454 Life Sciences Corporation, a Roche Diagnostics Roche Company Dr. Burkhard Ziebolz Dr. Ulrich Schwoerer Phone: +49-8856-604830 Phone: +1-203-871-2300 Email: burkhard.ziebolz@roche.com Email: ulrich.schwoerer@roche.com


'/>"/>
SOURCE Roche Diagnostics GmbH
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. American Heart Association EMS Survey Uncovers Deficiencies in Response, Treatment and Transfer of Patients With Most Deadly Heart Attacks
2. Consumers at Risk: One in Six Wood Pallets in Los Angeles Discovered With Potentially Deadly Pathogens
3. New Study Released Today Showed Patients With Deadly Form of Lung Cancer Lived Longer Without Disease Worsening
4. Life Technologies Develops Fast and Accurate Test to Detect Europes Deadly E. coli
5. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
6. Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions
7. New Study Shows Probiotic Strain Effective in Improving Irritable Bowel Syndrome Symptoms
8. New Study Shows Probiotic Strain Effective in Boosting Immune Response to Flu Virus
9. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
10. Lakewood-Amedex Inc. to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains
11. Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 16, 2017  Newly published research from the CVS ... the role a private retailer can play in restricting ... published online today in the American Journal of ... remove tobacco from all CVS Pharmacy stores reduced the ... an even greater impact on those who bought cigarettes ...
(Date:2/16/2017)... -- Summary Provides understanding and access to the ... healthcare companies. ... The Global Allergy Partnering Terms and Agreements since 2010 report ... by the world,s leading healthcare companies. - Trends ... Deals listed by company A-Z, industry sector, stage of development, technology ...
(Date:2/16/2017)... , Feb 16, 2017 Research and Markets ... Diagnostics Market Analysis & Trends - Function, Application, Cancer Type, Technology ... ... Cancer Diagnostics Market is poised to grow at a CAGR of ... by 2025. Some of the prominent trends ...
Breaking Medicine Technology:
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, ... join forces with Healthwise ® at HIMSS 2017 to showcase ... in evidence-based health education, technology and services, will demonstrate a voice-powered knowedge assistant ...
(Date:2/18/2017)... ... February 17, 2017 , ... Park Cities Pet Sitter President, Joette ... the Pet Life Radio network. The episode, which was posted this week, features ... what factors led to Park Cities Pet Sitter’s being awarded the 2017 National Association ...
(Date:2/17/2017)... ... 17, 2017 , ... The Alliance Healthcare Foundation (AHF) announced ... positively impact the health and wellness of our community in San Diego and ... to seriously consider releasing our assets beyond our 5% targeted distribution each year ...
(Date:2/17/2017)... VA (PRWEB) , ... February 17, 2017 , ... ... the Steps to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 ... , Do manufacturers distinguish between corrective action (CA) and preventive action (PA)? , ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... executives and focusing on all facets of clinical trial planning and management. Pharmica ... patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were able ...
Breaking Medicine News(10 mins):